Time filter

Source Type

Seattle, WA, United States

Koronis Pharmaceuticals is a Seattle area biotechnology company founded in 1998. Koronis is dedicated to the development of antiviral therapeutics based on a novel mechanism, Viral Decay Acceleration . The Company’s lead product candidate is KP-1461 for the treatment of human immunodeficiency virus infection. The company also has products in development for the treatment of hepatitis C and RSV infection. Wikipedia.

Clay P.G.,University of Kansas | McRae M.P.,University of Kansas | Laurent J.-P.,Koronis Pharmaceuticals
Journal of the International Association of Physicians in AIDS Care | Year: 2011

Background: KP-1461 is a prodrug to KP-1212. KP-1212 is a viral mutagen designed to increase viral error rate. Methods: We describe 2 phase I studies: KP1461-101 (double-blind, placebo-controlled, single, escalating doses, 100 to 1600 mg study in 42 non-HIV-infected participants) and KP-1461-102 (double-blind placebo-controlled dose escalation 14-day study in HIVinfected participants, 400-3200 mg). Primary objectives were safety/tolerability. Secondary objectives included pharmacokinetic analysis with exploratory objective to characterize KP-1212 effects on viral load. Results: KP-1461 was well tolerated. Majority of adverse events were grade 1 (neurological, gastrointestinal, cardiovascular). Four participants experienced grade 3 and 1experienced a grade 4 event. Analysis demonstrated no difference in pharmacokinetic parameters at day 1 or 14. Linear pharmacokinetics found in 1600 mg arm. Compared to placebo, only at the 3200 mg dose demonstrated a marginally statistically significant virologic response. Conclusions: These studies provide safety/tolerability information and suggest virologic efficacy. KP-1212, a first-in-class antiretroviral, demonstrates the ability to induce viral eradication in vitro. Viral reduction in vivo may foretell a paradigm shift in HIV pharmacotherapy. © The Author(s) 2011.

Koronis Pharmaceuticals | Date: 2005-10-25

therapeutic biochemicals, namely, nucleosides and nucleotides, and compounds containing nucleosides and nucleotides, for medical, clinical, scientific and research use.

Koronis Pharmaceuticals | Date: 2002-09-11

therapeutic biochemicals, namely, nucleosides, nucleotides and compounds containing nucleosides and/or nucleotides, sold primarily through pharmacies to patients for oral administration.

Koronis Pharmaceuticals | Date: 2006-06-06

pharmaceutical preparations, namely, compounds containing nucleosides and nucleotides for use in the treatment of human viral pathogens.


Koronis Pharmaceuticals | Date: 2006-06-06

pharmaceutical preparations containing nucleosides and nucleotides for use in the treatment of human viral pathogens.

Discover hidden collaborations